<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 4 0 Somewhat Bullish 1 1 4 1 Indifferent 0 1 5 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 18 analysts have offered 12-month price targets for Biogen. The company has an average price target of $428.61 with a high of $647.00 and a low of $245.00.
...read full article on Benzinga
